GB201314926D0 - Novel Compounds - Google Patents

Novel Compounds

Info

Publication number
GB201314926D0
GB201314926D0 GBGB1314926.5A GB201314926A GB201314926D0 GB 201314926 D0 GB201314926 D0 GB 201314926D0 GB 201314926 A GB201314926 A GB 201314926A GB 201314926 D0 GB201314926 D0 GB 201314926D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1314926.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to GBGB1314926.5A priority Critical patent/GB201314926D0/en
Publication of GB201314926D0 publication Critical patent/GB201314926D0/en
Priority to TW103128316A priority patent/TW201536722A/zh
Priority to UY0001035708A priority patent/UY35708A/es
Priority to KR1020167007214A priority patent/KR20160045797A/ko
Priority to CN201480046178.8A priority patent/CN105473548B/zh
Priority to MA38854A priority patent/MA38854B1/fr
Priority to US14/463,780 priority patent/US9464060B2/en
Priority to JP2016535530A priority patent/JP6422974B2/ja
Priority to AU2014310404A priority patent/AU2014310404B2/en
Priority to EA201690390A priority patent/EA028818B1/ru
Priority to HK16113982.5A priority patent/HK1225712A1/zh
Priority to TN2016000061A priority patent/TN2016000061A1/en
Priority to MX2016001896A priority patent/MX2016001896A/es
Priority to EP14756117.9A priority patent/EP3036215A1/en
Priority to PE2016000269A priority patent/PE20160284A1/es
Priority to SG11201601250TA priority patent/SG11201601250TA/en
Priority to US14/913,135 priority patent/US10100018B2/en
Priority to ARP140103129A priority patent/AR097403A1/es
Priority to PCT/GB2014/052558 priority patent/WO2015025164A1/en
Priority to CA2921742A priority patent/CA2921742A1/en
Priority to IL243780A priority patent/IL243780A0/en
Priority to ZA2016/00753A priority patent/ZA201600753B/en
Priority to PH12016500322A priority patent/PH12016500322A1/en
Priority to CL2016000387A priority patent/CL2016000387A1/es
Priority to CR20160084A priority patent/CR20160084A/es
Priority to US15/999,570 priority patent/US20190010129A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB1314926.5A 2013-08-20 2013-08-20 Novel Compounds Ceased GB201314926D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB1314926.5A GB201314926D0 (en) 2013-08-20 2013-08-20 Novel Compounds
TW103128316A TW201536722A (zh) 2013-08-20 2014-08-18 新穎化合物
UY0001035708A UY35708A (es) 2013-08-20 2014-08-19 Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
CA2921742A CA2921742A1 (en) 2013-08-20 2014-08-20 Amide derivatives as lysophosphatidic acid receptor antagonists
MX2016001896A MX2016001896A (es) 2013-08-20 2014-08-20 Derivados de amida como agonistas del receptor del ácido lisofosfatídico.
PE2016000269A PE20160284A1 (es) 2013-08-20 2014-08-20 Derivados de amida como antogonistas del receptor de acido lisofosfatidico
MA38854A MA38854B1 (fr) 2013-08-20 2014-08-20 Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
US14/463,780 US9464060B2 (en) 2013-08-20 2014-08-20 Compounds
JP2016535530A JP6422974B2 (ja) 2013-08-20 2014-08-20 リゾホスファチジン酸受容体拮抗薬としてのアミド誘導体
AU2014310404A AU2014310404B2 (en) 2013-08-20 2014-08-20 Amide derivatives as lysophosphatidic acid receptor antagonists
EA201690390A EA028818B1 (ru) 2013-08-20 2014-08-20 Производные амидов в качестве антагонистов рецептора к лизофосфатидной кислоте
HK16113982.5A HK1225712A1 (zh) 2013-08-20 2014-08-20 作爲溶血磷脂酸受体拮抗剂的酰胺衍生物
TN2016000061A TN2016000061A1 (en) 2013-08-20 2014-08-20 Amide derivatives as lysophosphatidic acid receptor antagonists
KR1020167007214A KR20160045797A (ko) 2013-08-20 2014-08-20 리소포스파티드산 수용체 길항제로서의 아미드 유도체
EP14756117.9A EP3036215A1 (en) 2013-08-20 2014-08-20 Amide derivatives as lysophosphatidic acid receptor antagonists
CN201480046178.8A CN105473548B (zh) 2013-08-20 2014-08-20 作为溶血磷脂酸受体拮抗剂的酰胺衍生物
SG11201601250TA SG11201601250TA (en) 2013-08-20 2014-08-20 Amide derivatives as lysophosphatidic acid receptor antagonists
US14/913,135 US10100018B2 (en) 2013-08-20 2014-08-20 Amide derivatives as lysophosphatidic acid receptor antagonists
ARP140103129A AR097403A1 (es) 2013-08-20 2014-08-20 Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación
PCT/GB2014/052558 WO2015025164A1 (en) 2013-08-20 2014-08-20 Amide derivatives as lysophosphatidic acid receptor antagonists
IL243780A IL243780A0 (en) 2013-08-20 2016-01-26 Amide derivatives as lysophosphatidic acid receptor agonists
ZA2016/00753A ZA201600753B (en) 2013-08-20 2016-02-03 Amide derivatives as lysophosphatidic acid receptor antagonists
PH12016500322A PH12016500322A1 (en) 2013-08-20 2016-02-18 Amide derivatives as lysophosphatidic acid receptor antagonists
CL2016000387A CL2016000387A1 (es) 2013-08-20 2016-02-19 Derivados de amida como antagonistas de ácido receptor lisofosfatidico
CR20160084A CR20160084A (es) 2013-08-20 2016-02-19 Derivados de amida como agonistas del receptor del ácido lisofosfatídico
US15/999,570 US20190010129A1 (en) 2013-08-20 2018-08-20 Amide derivatives as lysophosphatidic acid receptor antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1314926.5A GB201314926D0 (en) 2013-08-20 2013-08-20 Novel Compounds

Publications (1)

Publication Number Publication Date
GB201314926D0 true GB201314926D0 (en) 2013-10-02

Family

ID=49301993

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1314926.5A Ceased GB201314926D0 (en) 2013-08-20 2013-08-20 Novel Compounds

Country Status (24)

Country Link
US (3) US10100018B2 (enExample)
EP (1) EP3036215A1 (enExample)
JP (1) JP6422974B2 (enExample)
KR (1) KR20160045797A (enExample)
CN (1) CN105473548B (enExample)
AR (1) AR097403A1 (enExample)
AU (1) AU2014310404B2 (enExample)
CA (1) CA2921742A1 (enExample)
CL (1) CL2016000387A1 (enExample)
CR (1) CR20160084A (enExample)
EA (1) EA028818B1 (enExample)
GB (1) GB201314926D0 (enExample)
HK (1) HK1225712A1 (enExample)
IL (1) IL243780A0 (enExample)
MA (1) MA38854B1 (enExample)
MX (1) MX2016001896A (enExample)
PE (1) PE20160284A1 (enExample)
PH (1) PH12016500322A1 (enExample)
SG (1) SG11201601250TA (enExample)
TN (1) TN2016000061A1 (enExample)
TW (1) TW201536722A (enExample)
UY (1) UY35708A (enExample)
WO (1) WO2015025164A1 (enExample)
ZA (1) ZA201600753B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201314926D0 (en) * 2013-08-20 2013-10-02 Takeda Pharmaceutical Novel Compounds
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP7173350B2 (ja) 2019-07-30 2022-11-16 大正製薬株式会社 Ｌｐａ１受容体を拮抗するウレア化合物
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
AU2021282986B2 (en) 2020-06-03 2024-03-07 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
KR20240005892A (ko) 2021-05-11 2024-01-12 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
AU2022405082B2 (en) 2021-12-08 2025-09-25 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2024252334A1 (en) * 2023-06-06 2024-12-12 Gpcr Therapeutics, Inc. Gpcr inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707641B1 (fr) * 1993-07-16 1995-08-25 Fournier Ind & Sante Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique.
ES2239203T3 (es) 2001-01-31 2005-09-16 Pfizer Products Inc. Derivados nicotinamida y sus mimeticos como inhibidores de isozimas pde4.
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
TW200400930A (en) * 2002-06-26 2004-01-16 Ono Pharmaceutical Co Therapeutic agent for chronic disease
EP1553075B1 (en) * 2002-10-03 2013-08-14 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
IN2012DN00754A (enExample) * 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
WO2011037192A1 (ja) 2009-09-25 2011-03-31 アステラス製薬株式会社 置換アミド化合物
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
PH12012500542A1 (en) * 2010-09-24 2012-11-12 Astellas Pharma Inc Substituted amide compound
US8785442B2 (en) 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
EP2765128A1 (en) * 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
GB201314926D0 (en) 2013-08-20 2013-10-02 Takeda Pharmaceutical Novel Compounds

Also Published As

Publication number Publication date
EA028818B1 (ru) 2018-01-31
CA2921742A1 (en) 2015-02-26
WO2015025164A1 (en) 2015-02-26
EP3036215A1 (en) 2016-06-29
AR097403A1 (es) 2016-03-09
CL2016000387A1 (es) 2016-12-16
PH12016500322A1 (en) 2016-05-02
MX2016001896A (es) 2016-05-26
US20160207880A1 (en) 2016-07-21
US10100018B2 (en) 2018-10-16
KR20160045797A (ko) 2016-04-27
US9464060B2 (en) 2016-10-11
SG11201601250TA (en) 2016-03-30
MA38854B1 (fr) 2018-05-31
US20150057298A1 (en) 2015-02-26
CN105473548A (zh) 2016-04-06
PE20160284A1 (es) 2016-04-27
EA201690390A1 (ru) 2016-08-31
MA38854A1 (fr) 2017-07-31
JP2016528274A (ja) 2016-09-15
CR20160084A (es) 2016-05-27
ZA201600753B (en) 2019-07-31
TW201536722A (zh) 2015-10-01
HK1225712A1 (zh) 2017-09-15
AU2014310404B2 (en) 2018-07-12
CN105473548B (zh) 2018-03-23
AU2014310404A1 (en) 2016-03-10
IL243780A0 (en) 2016-04-21
UY35708A (es) 2014-12-31
JP6422974B2 (ja) 2018-11-14
TN2016000061A1 (en) 2017-07-05
US20190010129A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
GB201311910D0 (en) Novel Compounds
GB201311888D0 (en) Novel compounds
GB201309085D0 (en) Compounds
AP2015008713A0 (en) Tetrahydropyrrolothiazine compounds
GB201302927D0 (en) Compounds
GB201309508D0 (en) Compounds
GB201317363D0 (en) Novel compounds
GB201318222D0 (en) Novel compounds
GB201314926D0 (en) Novel Compounds
AP3850A (en) Azetidinyloxyphenylpyrrolidine compounds
GB201322512D0 (en) Novel compounds
GB201320021D0 (en) Novel Compounds
EP2948457A4 (en) COMPOUNDS
GB201306794D0 (en) Compounds
EP2970113A4 (en) NOVEL CONNECTIONS
GB201316764D0 (en) Novel compounds
GB201316762D0 (en) Novel compounds
GB201310460D0 (en) Compounds
GB201401185D0 (en) Novel compounds
GB201321976D0 (en) Novel compounds
GB201321977D0 (en) Novel compounds
GB201321975D0 (en) Novel compounds
GB201321972D0 (en) Novel compounds
GB201321811D0 (en) Novel compounds
GB201319354D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)